Through additional preclinical data and clinical trials that explore the efficacy of IL-17 neutralization for IPF, the usefulness of IL-17-related monoclonal antibodies in IPF should be considered. This evidence concerns the gene IL17A and idiopathic pulmonary fibrosis.